# BostonGene Receives Frost & Sullivan's 2026 Global Company of the Year for Advancing in AI-Driven Multimodal Oncology Platforms

- Link: https://www.thailand-business-news.com/pr-news/bostongene-receives-frost-sullivans-2026-global-company-of-the-year-for-advancing-in-ai-driven-multimodal-oncology-platforms
- Published: 2026-05-05T21:00:00+07:00
- Author: PR Newswire

_Recognition highlights BostonGene’s leadership in improving __drug development 
decisions,
reducing risk and accelerating patient impact

SAN ANTONIO, May 5, 2026 /PRNewswire/ — [Frost & Sullivan](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4680492-1&h=3764942837&u=https%3A%2F%2Fwww.frost.com%2F&a=Frost+%26+Sullivan)
is pleased to announce that [BostonGene](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4680492-1&h=461020742&u=https%3A%2F%2Fbostongene.com%2F&a=BostonGene)
has been recognized as the 2026 Global Company of the Year in AI-Driven Multimodal
Oncology Platforms. This recognition highlights BostonGene’s leadership in improving
drug development decisions through its AI foundation model of tumor and immune biology.

Frost & Sullivan evaluates companies through a rigorous benchmarking process across
strategy effectiveness and execution. BostonGene was recognized for its unique ability
to translate complex biological data insights into actionable decisions that directly
impact development outcomes, including patient selection, trial design and therapeutic
strategy.

Drug development is fundamentally a sequence of high-stakes decisions: what to build,
which patients to treat, and how to design and execute trials. BostonGene addresses
this by modeling disease as a dynamic biological system and simulating how tumors
and the immune system respond to therapeutic intervention. BostonGene integrates
real multimodal data, including genomic, transcriptomic, immune, clinical, and imaging
signals. This enables pharmaceutical teams to make more informed decisions before
critical investments and trials begin. This approach allows partners to identify
optimal indications, refine biomarker strategies, improve patient selection, and
better understand mechanisms of response and resistance. The result is a shift from
retrospective analysis to forward-looking decision-making. This transition improves
the probability of success while reducing development costs, timelines, and risk,
enabling better decisions before critical investments are made.

"BostonGene is moving oncology AI beyond retrospective analytics toward biologically
grounded predictions that improve decision-making earlier in development. By embedding
these capabilities into active development programs, the company enables sponsors
to better assess therapy response, safety, and patient selection before critical
investment and trial design decisions are made," said Surbhi Gupta, Industry Principal
at Frost & Sullivan.

BostonGene’s growth strategy is anchored in its multimodal approach, which utilizes
the simultaneous analysis of tumor and immune biology to decode the full complexity
of the cancer landscape. This differentiated position allows biopharma partners 
to refine biomarker strategies and optimize trial designs with a level of analytical
confidence previously unavailable in the industry.

"This recognition from Frost & Sullivan reflects where the industry is heading,"
said Nathan Fowler, MD, Chief Medical Officer at BostonGene. "By modeling biology
and simulating response to treatment, we help our partners make better decisions
earlier, which ultimately determines clinical and economic outcomes."

BostonGene also distinguishes itself through its ability to operationalize these
capabilities within its CLIA-certified, CAP-accredited laboratory, ensuring that
its AI-driven insights meet the regulatory-grade standards required for global clinical
trials and real-world implementation. Its focus on measurable clinical and economic
value has made it a trusted partner to leading biopharma organizations.

Read the official report here: [https://www.frost.com/wp-content/uploads/2026/05/BostonGene-Final-Report.pdf](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4680492-1&h=1244245056&u=https%3A%2F%2Fwww.frost.com%2Fwp-content%2Fuploads%2F2026%2F05%2FBostonGene-Final-Report.pdf&a=https%3A%2F%2Fwww.frost.com%2Fwp-content%2Fuploads%2F2026%2F05%2FBostonGene-Final-Report.pdf)

Frost & Sullivan commends BostonGene for setting a high standard in competitive 
strategy, execution, and market responsiveness. The company’s vision, innovation
pipeline, and customer-first culture are shaping the future of AI-Driven Multimodal
Oncology Platforms and driving tangible results at scale.

Each year, Frost & Sullivan presents the Company of the Year award to the organization
that demonstrates outstanding strategy development and implementation, resulting
in measurable improvements in market share, customer satisfaction, and competitive
positioning. The recognition identifies forward-thinking organizations that are 
reshaping their industries through innovation and growth excellence.

**Frost & Sullivan Best Practices Recognition**

Frost & Sullivan’s Best Practices Recognitions honor companies across regional and
global markets that exhibit exceptional achievement and consistent excellence in
areas such as leadership, technological innovation, customer experience, and strategic
product development. Each recognition is the result of a rigorous analytical process
in which Frost & Sullivan industry experts benchmark performance through comprehensive
interviews, deep-dive analysis, and extensive secondary research. The goal is to
identify true best-in-class organizations that are driving transformative growth
and setting new industry standards.
[**Contact us: Start the discussion**](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4680492-1&h=1240790847&u=https%3A%2F%2Fww2.frost.com%2Fcontact-us%2F&a=Contact+us%3A+Start+the+discussion)**.**

Contact:
Ashley ShreveE: [ashley.weinkauf@frost.com](https://www.thailand-business-news.com/pr-news/ashley.weinkauf@frost.com)

**About BostonGene**

BostonGene powers an AI foundation model of tumor and immune biology to deliver 
disease-level insights and enable precision decision-making across oncology and 
immune-mediated diseases, spanning drug development and clinical care. By integrating
multimodal data, including genomic, transcriptomic, immune, and clinical signals,
BostonGene generates biologically grounded intelligence to optimize patient selection,
trial design, and therapeutic strategy. This creates a scalable AI decision layer
that improves development outcomes and clinical management. BostonGene partners 
with leading biopharmaceutical organizations and academic institutions to accelerate
the delivery of precision therapies while continuously expanding its capabilities
across new diseases and complex biological systems. For more information, visit 
[www.BostonGene.com](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4680492-1&h=1135569742&u=https%3A%2F%2Fwww.bostongene.com%2F&a=www.BostonGene.com).

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [BostonGene Receives Frost & Sullivan's 2026 Global Company of the Year for Advancing in AI-Driven Multimodal Oncology Platforms ](http://www.prnasia.com/story/archive/4950935_AE50935_0?rand=184833)